OR WAIT null SECS
Making the Grade: The Importance of Using the Correct Excipient Grade in Drug Products
With an ever-growing market driving technological advances, there is always work to be done in drug manufacturing.
Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.
Packaging and packaging line innovations are addressing the industry’s growing use of biologics.
What are the lessons gleaned from a product’s E&L lifetime?
There are considerations companies may want to consider before seeking out a service provider.
The Biosimilars Landscape
May 01, 2024
The CDMO plans to expand and upgrade its Philadelphia, Ohio, and Milan facilities to meet the continued growth in demand for high potency handling capabilities.
Josh Hirshenhorn (Sales Representative, Rees Scientific) explains current challenges faced by pharmaceutical and biotech companies and how Rees' continuous monitoring systems offer solutions.
April 30, 2024
Key areas to invest include manufacturing process improvements, quality management, and AI.
Meeta B. Kratz (Global Vice President, Product Management & Marketing, Lonza Capsule and Health Ingredients) talks about Lonza's future and how that works in tandem to meet client needs.
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
April 29, 2024
The non-profit initiative puts collaboration at the forefront as it tackles the challenges surrounding recycling primary pharmaceutical packaging.
The agreement, which will allow participants to share confidential information on medical and medicinal products, builds on the cooperation fostered between the two regulatory authorities during the COVID-19 pandemic.
Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies
Bill Humphries (CEO, Alcami) dives into an overview of Alcami's capabilities and how they value their client's innovations.
April 27, 2024
SK pharmteco, a CDMO, will manufacture, test, and release Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy from Ferring Pharmaceuticals for treating bladder cancer.